Penumbra's Stock Sees 15.08% Increase, Reaching $208.80 on November 13

Penumbra Stock Price 

As of November 13th, 2023, Penumbra (NYSE: PEN) is trading at $208.80  per share, marking a notable increase of 15.08% today. This surge in stock value underscores the company's strong performance in the medical technology sector, where it specializes in developing cutting-edge devices for neurovascular and peripheral vascular applications. Investors are likely responding positively to Penumbra advancements and innovations, contributing to the notable uptick in its stock price.

Penumbra Stock Analysis

Penumbra , listed on the New York Stock Exchange under the symbol PEN, displayed notable activity on November 13th. The stock opened at $211.87 and reached a high of $223.04, with a low of $202.48. The closing price stood at $208.80, marking a significant increase of $27.36 (15.08%) for the day. The company's market capitalization was reported at $8.06 billion , with a 52-week high of $348.67 and a 52-week low of $180.93. The closing price on November 13th was substantially higher than the previous close of $181.44, underlining the day's positive momentum.

Penumbra financial metrics reveal a P/E ratio of 200.84, indicating a relatively high valuation compared to earnings. The stock's average trading volume stood at 460.75K shares, reflecting a level of liquidity in the market. The company's performance over the past year has seen fluctuations within a wide range, suggesting both volatility and potential opportunities for investors.

Penumbra Stock Data

Here Are the Key Details for Penumbra  Stock:

Penumbra Profile

Penumbra, based in Alameda, California, is a medical device company founded in 2004. Specializing in the neuro/vascular market, it creates innovative devices for treating stroke and aneurysm. Notably, the 2014 launch of the Apollo system allows minimally invasive removal of brain tissue and fluids.

Penumbra went public on the NYSE in 2015, achieving financial success. In 2018, the company acquired a 40% stake in virtual reality venture MVI Health and expanded globally with the purchase of Italian distributor Crossmed in 2017. Penumbra's profile highlights its leadership in advancing medical technology.